Protalix Biotherapeutics, Inc. (PLX) - Q1 2025 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2025. Protalix Biotherapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing recombinant therapeutic proteins using its proprietary ProCellEx plant cell-based expression system. The company's primary commercial products are Elelyso (for Gaucher disease) and Elfabrio (for Fabry disease). Operations are primarily conducted in Israel, with commercialization partnerships including Pfizer (Elelyso), Chiesi (Elfabrio), and Fiocruz (Elelyso in Brazil).
Key Financial Metrics
| Metric (in thousands) | Q1 2025 | Q1 2024 |
|---|---|---|
| Total Revenue | $10,113 | $3,748 |
| Cost of Goods Sold | $(8,180) | $(2,602) |
| Gross Profit | $1,933 | $1,146 |
| Operating Loss | $(4,145) | $(4,856) |
| Net Loss | $(3,619) | $(4,595) |
| Loss Per Share (Basic & Diluted) | $(0.05) | $(0.06) |
| Cash and Cash Equivalents | $19,458 | $27,209 |
| Short-term Bank Deposits | $15,285 | $15,070 |
| Total Liquidity (Cash + Deposits) | $34,743 | $42,279 |
| Net Cash Used in Operating Activities | $(5,058) | $4,188 |
| Net Cash Provided by Financing Activities | $5,076 | $0 |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased by 170% to $10.1 million, driven primarily by a $5.9 million increase in sales to Pfizer (Elelyso) and a $0.4 million increase in sales to Fiocruz (Brazil).
- Cost of Goods Sold (COGS): COGS rose 215% to $8.2 million, directly correlating with the volume increase in product sales.
- Operating Expenses: R&D expenses increased 21% to $3.5 million due to pipeline advancement. SG&A expenses decreased 16% to $2.6 million.
- Debt Repayment: The company fully repaid its 7.50% Senior Secured Convertible Promissory Notes in September 2024, eliminating significant interest expenses seen in the prior year ($390k in Q1 2024 vs. $6k in Q1 2025).
- Equity Financing: The company raised approximately $5.1 million in Q1 2025 through the issuance of common stock under its Sales Agreement ($2.9 million net) and the exercise of warrants ($2.2 million).
Outlook, Risks, and Management Commentary
- Liquidity Position: Management believes current cash and short-term deposits ($34.7 million) are sufficient to fund operations for at least 12 months from the filing date.
- Product Pipeline: The company is advancing PRX-115 (PEGylated uricase for gout) and expects to commence a Phase II clinical trial in the second half of 2025. PRX-119 (DNase I for NETs-related diseases) remains in development.
- Geopolitical Risk: Operations in Israel face risks from ongoing regional conflict (Hamas, Hezbollah, Iran). While the company has stored drug substance in multiple locations to mitigate risk, the filing notes that the duration and severity of the conflict remain unpredictable.
- Commercialization: Elfabrio commercialization with Chiesi is ongoing. The company is evaluating a 2 mg/kg every four weeks dosing regimen for Elfabrio, which has received a positive opinion from the EMA for a variation submission.
- Financing: The company amended its Sales Agreement in March 2025 to increase the available offering size by $20.0 million. Approximately $19.7 million remains available for sale under this agreement.
Key Facts for Investor Verification
- Cash Burn Rate: Verify the sustainability of the $5.1 million net cash outflow from operations against the $34.7 million liquidity buffer.
- Revenue Concentration: Confirm the stability of the Pfizer and Fiocruz supply agreements, which accounted for nearly all product revenue ($9.995 million of $10.113 million total).
- Elfabrio Milestones: Monitor Chiesi's commercial performance of Elfabrio, as Protalix's future revenue is heavily dependent on tiered royalty payments and milestones from this partner.
- Geopolitical Impact: Assess any potential disruption to manufacturing in Israel or supply chain logistics due to the ongoing regional conflict.
- Equity Dilution: Track the utilization of the amended Sales Agreement, as the company relies on equity financing to fund R&D and operations.